Current advances in the development of anticancer drugs targeting tyrosine kinases of the Src family

Current Drug Therapy

Volumn 3, Issue 3, 2008, Pages 158-176

  Schenone, Silvia ^a   Zanoli, Samantha ^b   Brullo, Chiara ^a   Crespan, Emmanuele ^b   Maga, Giovanni ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b CNR   (Italy)

Author keywords

Angiogenesis; Anticancer chemotherapy; Anticancer Drugs; Cell proliferation signals; Inhibitors; Signal Transduction; Src family; Tumor cells; Tyrosine Kinases

Indexed keywords

4 AMINO 7 PHENYLPYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; AP 23451; AP 23846; BOSUTINIB; CGP 77675; DASATINIB; IMATINIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PP 3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRIDYL N OXIDE VINYL DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDO[5,4 B]QUINOLONE DERIVATIVE; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; QUINOLONE DERIVATIVE; SKS 927; SPRYCELL; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HYPERCALCEMIA; MALIGNANT NEOPLASTIC DISEASE; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSIENT ISCHEMIC ATTACK;

EID: 54849438333     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488508785747862     Document Type: Review

References (168)

1. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004; 23: 7918-27.
2. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004; 23: 7957-68.
3. Gauld SB, Cambier JC. Src-family kinases in B-cell development and signaling. Oncogene 2004; 23: 8001-6.
4. Geahlen RL, Handley MD, Harrison ML. Molecular interdiction of Src-family kinase signaling in hematopoietic cells. Oncogene 2004; 23: 8024-32.
5. Luttrell DK, Luttrell LM. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 2004; 23: 7969-78.
6. Martin GS. The road to Src. Oncogene 2004; 23: 7910-7.
7. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004; 23: 7990-8000.
8. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogen 2004; 23: 7906-9.
9. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004; 23: 7928-46.
10. Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 2004; 23: 7947-56.
11. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004; 23: 7979-89.
12. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-23.
13. Alvarez RH, Kantarjian HM, Cortes YE. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 2006; 107: 1918-29.
14. Trevino JG, Summy JM, Gallick GE. SRC inhibitors as potential therapeutic agents for human cancels. Mini Rev Med Chem 2006; 6: 681-7.
15. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006; 12: 1398-401.
16. Alper O, Bowden ET. Novel insights into c-Src. Curr Pharm Des 2005; 11: 1119-30.
17. Roskoski R, Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005; 331: 1-14.
18. Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000; 254: 1-13.
19. Ralston R, Bishop JM. The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor. Proc Natl Acad Sci USA 1985; 82: 7845-9.
20. Mori S, Ronnstrand L, Yokote K, et al. Identification of two jux-tamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J 1993; 12: 2257-64.
21. Twamley GM, Kypta RM, Hall B, Courtneidge SA. Association of Fyn with the activated platelet-derived growth factor receptor: requirements for binding and phosphorylation. Oncogene 1992; 7: 1893-901.
22. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513-609.
23. Broome MA, Hunter T. The PDGF receptor phosphorylates Tyr 138 in the c-Src SH3 domain in vivo reducing peptide ligand binding. Oncogene 1997; 14: 17-34.
24. Belsches AP, Haskell MD, Parsons SJ. Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front Biosci 1997; 2: d501-18.
25. Stover DR, Furet P, Lydon NB. Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J Biol Chem 1996; 271: 12481-7.
26. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-5.
27. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999; 6: R217-24.
28. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
29. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-2.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
32. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
33. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-15.
34. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J 1992; 6: 2591-9.
35. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71.
36. Madhusudan S, Harris AL. Drug inhibition of angiogenesis. Curr Opin Pharmacol 2002; 2: 403-14.
37. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540-5.
38. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96: 4216-21.
39. Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001; 2: 278-89.
40. List AF. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 2001; 6: 24-31.
41. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-58.
42. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293-6.
43. Ha CH, Bennett AM, Jin ZG. A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor. J Biol Chem 2008; 283: 7261-70.
44. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006; 83: 1005-16.
45. Jemal A, Siegel R, Ward E, et al. Cancer J Clin 2006; 56: 106-30.
46. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000; 19: 5636-42.
47. Levin VA. Basis and importance of Src as a target in cancer. Cancer Treat Res 2004; 119: 89-119.
48. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
49. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5.
50. Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 2007; 7: 651-9.
51. Avizienyte E, Brunton VG, Fincham VJ, Frame MC. The SRC-induced mesenchymal state in late-stage colon cancer cells. Cells Tissues Organs 2005; 179: 73-80.
52. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 2007; 18: 371-5.
53. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002; 94: 344-51.
54. Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005; 17: 542-7.
55. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
56. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci U S A 1987; 84: 2251-5.
57. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W. pp60c-src activation in human colon carcinoma. J Clin Invest 1989; 83: 2025-33.
58. Fizazi K. The role of Src in prostate cancer. Ann Oncol 2007; 18: 1765-73.
59. Maurer GD, Leupold JH, Schewe DM, et al. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res 2007; 13: 1123-32.
60. van Oijen MG, Rijksen G, ten Broek FW, Slootweg PJ. Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J Oral Pathol Med 1998; 27: 147-52.
61. Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996; 180: 383-8.
62. Riggins RB, Thomas KS, Ta HQ, et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 2006; 66: 7007-15.
63. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453-61.
64. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2: 467-75.
65. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4: 470-80.
66. Mayer BJ. Signal transduction: clamping down on Src activity. Curr Biol 1997; 7: R295-8.
67. Sicheri F, Kuriyan J. Structures of Src-family tyrosine kinases. Curr Opin Struct Biol 1997; 7: 777-85.
68. Superti-Furga G, Gonfloni S. A crystal milestone: the structure of regulated Src. Bioessays 1997; 19: 447-50.
69. Williams JC, Wierenga RK, Saraste M. Insights into Src kinase functions: structural comparisons. Trends Biochem Sci 1998; 23: 179-84.
70. Cowan-Jacob SW, Fendrich G, Manley PW, et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005; 13: 861-71.
71. Feder D, Bishop JM. Purification and enzymatic characterization of pp60c-src from human platelets. J Biol Chem 1990; 265: 8205-11.
72. Sugimoto Y, Erikson E, Graziani Y, Erikson RL. Inter- and intramolecular interactions of highly purified Rous sarcoma virus-transforming protein, pp60v-src. J Biol Chem 1985; 260: 13838-43.
73. Osusky M, Taylor SJ, Shalloway D. Autophosphorylation of purified c-Src at its primary negative regulation site. J Biol Chem 1995; 270: 25729-32.
74. Cooper JA, MacAuley A. Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation. Proc Natl Acad Sci U S A 1988; 85: 4232-6.
75. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 2001; 105: 115-26.
76. Ulmer TS, Werner SM, Campbell ID. SH3-SH2 domain orientation in Src kinases: NMR studies of Fyn. Structure 2002; 10: 901-11.
77. Zheng XM, Resnick RJ, Shalloway D. A phosphotyrosine displacement mechanism for activation of Src by PTPalpha. EMBO J 2000; 19: 964-78.
78. Okada M, Nakagawa H. A protein tyrosine kinase involved in regulation of pp60c-src function. J Biol Chem 1989; 264: 20886-93.
79. Zrihan-Licht S, Lim J, Keydar I, Sliwkowski MX, Groopman JE, Avraham H. Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ ErbB-2 in breast cancer cells. J Biol Chem 1997; 272: 1856-63.
80. Roskoski R, Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 2004; 324: 1155-64.
81. Chong YP, Mulhern TD, Zhu HJ, et al. A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity. J Biol Chem 2004; 279: 20752-66.
82. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 2000; 275: 41439-46.
83. Yang J, Liu L, He D, et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem 2003; 278: 6516-20.
84. Zhang SQ, Yang W, Kontaridis MI, et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 2004; 13: 341-55.
85. Stover DR, Liebetanz J, Lydon NB. Cdc2-mediated modulation of pp60c-src activity. J Biol Chem 1994; 269: 26885-9.
86. Gil-Henn H, Elson A. Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells. J Biol Chem 2003; 278: 15579-86.
87. Burnham MR, Bruce-Staskal PJ, Harte MT, et al. Regulation of c-SRC activity and function by the adapter protein CAS. Mol Cell Biol 2000; 20: 5865-78.
88. Thomas JW, Ellis B, Boerner RJ, Knight WB, White GC, 2nd, Schaller MD. SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem 1998; 273: 577-83.
89. Lerner EC, Smithgall TE. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat Struct Biol 2002; 9: 365-9.
90. Trible RP, Emert-Sedlak L, Smithgall TE. HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem 2006; 281: 27029-38.
91. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformation. Nat Chem Biol 2006; 2: 358-64.
92. Stout TJ, Foster PG, Matthews DJ. High-throughput structural biology in drug discovery: protein kinases. Curr Pharm Des 2004; 10: 1069-82.
93. Parang K, Sun G. Recent advances in the discovery of Src kinase inhibitors. Expert Opin Ther Patents 2005; 15: 1183-207.
94. Wu SY, McNae I, Kontopidis G, et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (Camb) 2003; 11: 399-410.
95. Schenone S, Manetti F, Botta M. Synthetic SRC-kinase domain inhibitors and their structural requirements. Anticancer Agents Med Chem 2007; 7: 660-80.
96. Summy JM, Gallick GE. Treatment for advanced tumors: Src reclaims center stage. Clin Cancer Res 2006; 12: 1398-401.
97. Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies. Development of new-generation Src inhibitors. Cancer 2006; 107: 1918-29.
98. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 2007; 13: 7232-6.
99. Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996; 271: 695-701.
100. Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-8.
101. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999; 3: 639-48.
102. Zhu XT, Kim JL, Newcomb JR, et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999; 7: 651-61.
103. Karni R, Mizrachi S, Reiss-Sklan E, Gazit A, Livnah O, Levitzki A. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett 2003; 537: 47-52.
104. Tattoo L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 2003; 278: 4847-53.
105. Warmuth M, Simon N, Mitina O, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases Blood 2003; 101: 664-72.
106. Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of abl and SRC tyrosine-kinases. Mini Rev Med Chem 2007; 7: 191-201.
107. Sanna PP, Berton F, Cammalleri M, et al. A role for Src kinase in spontaneous epileptiform activity in the CA3 region of the hippocampus. Proc Natl Acad Sci USA 2000; 97: 8653-7.
108. Dickerson J, Sharp FR. Atypical antipsychotics and a Src kinase inhibitor (PP1) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801. Neuropsychopharmacology 2006; 31: 1420-30.
109. Hou XY, Liu Y, Zhang GY. PP2, a potent inhibitor of Src family kinases, protects against hippocampal CA1 pyramidal cell death after transient global brain ischemia. Neurosci Lett 2007; 420: 235-9.
110. Schenone S, Bruno O, Bondavalli F, et al. Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur J Med Chem 2004; 39: 939-46.
111. Carraro F, Pucci A, Naldini A, et al. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. J Med Chem 2004; 47: 1595-8.
112. Carraro F, Naldini A, Pucci A, et al. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem 2006; 49: 1549-61.
113. Angelucci A, Schenone S, Gravina GL, et al. Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. Eur J Cancer 2006; 42: 2338-45.
114. Donnini S, Monti M, Castagnini C, et al. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int J Cancer 2007; 120: 995-1004.
115. Manetti F, Santucci A, Locatelli G, et al. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 2007; 50: 5579-88.
116. Spreafico A, Schenone S, Serchi T, et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J 2008; 22: 156-71.
117. Celano M, Schenone S, Cosco D, et al. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr Relat Cancer 2008; 15: 499-510.
118. Manetti F, Pucci A, Magnani M, et al. inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells. Chem Med Chem 2007; 2: 343-353.
119. Boyce BF, Xing L, Yao Z, et al. Src inhibitors in metastatic bone disease. Clin Cancer Res 2006; 12: 6291s-6295s.
120. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 1999; 24: 437-49.
121. Recchia I, Rucci N, Funari A, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 2004; 34: 65-79.
122. Recchia I, Rucci N, Festuccia C, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003; 39: 1927-35.
123. Šuša M, Missbach M, Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 2000; 21: 489-95.
124. Missbach M, Altmann E, Wilder L, et al. Substituted 5,7-diphenyl-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2000; 10: 945-9.
125. Altmann E, Widler L, Missbach M. N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src. Mini Rev Med Chem 2002; 2: 201-8.
126. Altmann E, Missbach M, Green J, Šuša M, Wagenknecht H, Widler L. 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines-potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett 2001; 11: 853-6.
127. O'Hare T, Pollock R, Stoffregen EP, et al. inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004; 104: 2532-9.
128. Azam M, Nardi V, Shakespeare WC, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci USA 2006; 103: 9244-9.
129. Dalgarno D, Stehle T, Narula S, et al. Structural basis of Src Tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des 2006; 67: 46-57.
130. Dumas J, Smith RA, Lowinger TB. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Dev 2004; 7: 600-16.
131. Connolly CJC, Hamby JM, Schroeder MC, et al. Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Lett 1997; 7: 2415-20.
132. Schroeder MC, Hamby JM, Connolly CJC, et al. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J Med Chem 2001; 44: 1915-26.
133. Klutchko SR, Hamby JM, Boschelli DH, et al. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J Med Chem 1998; 41: 3276-92.
134. Panek RL, Lu GH, Klutchko SR, et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther 1997; 283: 1433-44.
135. Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth, Leukemia 1999; 13: 855-61.
136. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res 1999; 59: 6145-52.
137. Wisniewski D, Lambek CI, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002; 62: 4244-55.
138. Dimitroff CJ, Klohs W, Sharma A, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999; 17: 121-35.
139. Huron DR, Gorre ME, Kraker AJ, et al. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003; 9: 1267-73.
140. Kraker AJ, Hartl BJ, Amar A. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000; 60: 885-898.
141. La Rosée P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149-53.
142. Trumpp-Kallmeyer S, Rubin JR, Humblet C, Hamby JM, Showaltar HDH. Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem 1998; 41: 1752-63.
143. Palmer BD, Smaill JB, Rewcastle GW, et al. Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Weel. Bioorg Med Chem Lett 2005; 15: 1931-5.
144. Boschelli DH, Powell D, Golas JM, Boschelli F. Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines. Bioorg Med Chem Lett 2003; 13: 2977-80.
145. Mukaiyama H, Nishimura T, Shiohara H, et al. Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke. Chem Pharm Bull 2007; 55: 881-9.
146. Kr channel blockade. Bioorg Med Chem 2008; 16: 909-21.
147. Wang DY, Miller K, Boschelli DH, et al. Inhibitors of src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg Med Chem Lett 2000; 10: 2477-80.
148. Boschelli DH, Ye F, Wang DY, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001; 44: 3965-77.
149. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375-81.
150. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-22.
151. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005; 65: 5358-64.
152. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2007; 67: 1580-8.
153. Thaimattam R, Daga PR, Banerjee R, Iqbal J. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem 2005; 13: 4704-12.
154. Boschelli DH, Boschelli F, Wu B, et al. SKI-606 and beyond. Haematol Rep 2005; 1: 28-31.
155. Barrios Sosa AC, Boschelli DH, Wu B, Wang Y, Golas JM. Further studies on ethenyl and ethynyl-4-phenylamino-3-quinoline-carbonitriles: identification of a subnanomolar Src kinase inhibitor. Bioorg Med Chem Lett 2005; 15: 1743-7.
156. Wu B, Barrios Sosa AC, Boschelli DH, et al. 7-(Aryl/ heteroaryl-2-ylethynyl)-4-phenylamino-3-quinolinecarbonitriles as new Src kinase inhibitors: addition of water solubilizing groups. Bioorg Med Chem Lett 2006; 16: 3993-7.
157. Boschelli DH, Barrios Sosa AC, Golas JM, Boschelli F. Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett 2007; 17: 1358-61.
158. Boschelli DH, Wu B, Durutlic H, Golas JM, Lucas J, Boschelli F. Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs. Bioorg Med Chem 2008; 16: 405-12.
159. Boschelli DH, Wu B, Ye F, et al. Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl) amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem 2006; 49: 7868-76.
160. Berger DM, Dutia M, Birnberg G, et al. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors. J Med Chem 2005; 48: 5909-20.
161. Boschelli DH, Wu B, Barrios Sosa AC, et al. Identification of 7-phenylaminothieno-[3,2-b]pyridine-6-carbonitriles as a new class of Src kinase inhibitors. J Med Chem 2004; 47: 6666-8.
162. Boschelli DH, Wu B, Barrios Sosa AC, et al. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno [3,2-b]pyridine-6-carbonitriles. J Med Chem 2005; 48: 3891-902.
163. Boschelli DH, Wu B, Barrios Sosa AC, Chen JJ, Golan JM, Boschelli F. Inhibition of Src kinase activity by 7-[(2,4-dichloro- 5-methoxyphenyl)amino]- 2-heteroaryl- thieno[3,2-b] pyridine-6-carbonitriles. Bioorg Med Chem Lett 2005; 15: 4681-4.
164. Plé PA, Green TP, Hennequin LF, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 2004; 47: 871-87.
165. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004; 10: 8028-36.
166. Zheng R, Yano S, Matsumori Y, et al. Src tyrosine kinase inhibitor, M475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. Clin Exp Metastasis 2005; 22: 195-204.
167. Ali N, Yoshizumi M, Fujita Y, et al. A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci 2005; 98: 130-41.
168. Hennequin LF, Allen J, Breed J, et al.